January 3, 2019
The ADDF's Diagnostics Accelerator is matching a $2.5 million research investment from The Association for Frontotemporal Degeneration to invest in biomarkers for frontotemporal dementia.
July 13, 2018
The Alzheimer's Drug Discovery Foundation (ADDF) announces seven new investments, including clinical trials, novel drug programs, and a prevention program, which reflects the comprehensive nature of the ADDF's funding strategy.
May 11, 2018
Adam Rowe recounts a harrowing experience with his mother, who has frontotemporal dementia.
March 13, 2018
The ADDF announces two investments in programs targeting mitochondria and the progranulin gene.
February 21, 2018
While Alzheimer's accounts for more than two-thirds of dementia cases, the ADDF also funds research to prevent and treat the other causes of dementia.
September 5, 2017
The ADDF announces two new grants, including support for a blood test designed to detect Alzheimer’s disease in early stages of development and a gene therapy for frontotemporal dementia.
June 20, 2017
Our CSO Dr. Fillit explains the differences between Alzheimer's and dementia, two terms often used interchangeably.
April 20, 2017
A team of scientists from the Medical Research Council (MRC) in the UK have found two drugs, which block brain cell death and prevent neurodegeneration in preclinical studies. Their findings were published today in Brain.
March 7, 2017
We recently awarded eight new grants totaling over $4 million to advance treatments for Alzheimer’s and related dementias. Several of the awards support new approaches to treating these diseases.
November 15, 2016
On November 14, Donald Newhouse received The Charles Evans Award from the ADDF at our Seventh Annual Fall Symposium & Luncheon at The Pierre in New York City. Thanks to the generosity of our donors, the Symposium & Luncheon raised nearly $1 million for drug discovery research.